Skip to main content

Table 2 Safety and efficacy variables of the study presented as mean and difference in means (95% confidence interval)

From: APCAP - activated protein C in acute pancreatitis: a double-blind randomized human pilot trial

  N APC   Placebo Difference in means between the study groups (95% CI)
Delta SOFA score 16 1.8 (4.3) 16 -0.6 (4.1) 2.3 (-0.7 to 5.2)
Delta-non-hepatic SOFA 16 1.9 (4.1) 16 -0.2 (3.9) 2.1 (-0.8 to 4.9)
Ventilator free days 16 10.4 (9.4) 16 10.4 (11.5) 0 (-7.4 to 7.4)
Renal replacement therapy-free days 16 52.7 (12.7) 16 55.3 (9.3) -2.6 (-10.5 to 5.3)
Vasopressor-free days 16 52.8 (7.1) 16 55.1 (6.0) -2.6 (-5.9 to 2.3)
Alive outside hospital - days 16 17.1 (32.5) 16 34.4 (13.0) -17.4 (-0.1 to -34.9)
Delta modified CT score 11 0.5 (2.0) 11 0.5 (1.8) 0 (-1.6 to 1.6)
Delta serum bilirubin, total (μmol/L) 16 18 (46.4) 16 -10 (17.0) 28 (3.6 to 53.1) *
Delta serum bilirubin, conjugated (μmol/L) 13 14 (31.9) 12 -11 (11.1) 25 (5.6 to 44.4) *
Delta serum creatinine (μmol/L) 16 -37 (84) 16 13 (86) -50 (-110 to 10)
Delta platelet count (× 109/L) 16 32 (52) 16 35 (55) -3 (-40 to 34)
Delta plasma hemoglobin mg/L 13 -226 (499.5) 16 -65 (83.2) -161 (-413 to 92.0)
Delta serum pre-albumin mg/L 13 -50 (49.7) 12 -69 (55.2) 19 (-23.0 to 61.0)
  1. Organ-dysfunction-free days calculated for 60 days.
  2. *significant differences; CI, confidence interval.